Epstein-Barr virus: Environmental trigger of multiple sclerosis?

Journal of Virology

Volumn 81, Issue 13, 2007, Pages 6777-6784

  Lünemann, Jan D ^a   Kamradt, Thomas ^b   Martin, Roland ^c   Münz, Christian ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CROSS REACTING ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN; VIRUS ANTIBODY;

ANTIBODY TITER; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELLULAR IMMUNITY; ENVIRONMENTAL EXPOSURE; EPSTEIN BARR VIRUS; GENETIC SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; VIRUS CELL INTERACTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CHROMOSOMES, HUMAN, PAIR 6; ENVIRONMENT; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS; PREVALENCE; RISK FACTORS; SKIN DISEASES; T-LYMPHOCYTES; UNITED STATES;

HUMAN HERPESVIRUS 4;

EID: 34250859381     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00153-07     Document Type: Short Survey

References (87)

1. Alotaibi, S., J. Kennedy, R. Tellier, D. Stephens, and B. Banwell. 2004. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 291:1875-1879.
2. Antony, J. M., G. van Marie, W. Opii, D. A. Butterfield, F. Mallet, V. W. Yong, J. L. Wallace, R. M. Deacon, K. Warren, and C. Power. 2004. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat. Neurosci. 7:1088-1095.
3. Ascherio, A., K. L. Munger, E. T. Lennette, D. Spiegelman, M. A. Hernan, M. J. Olek, S. E. Hankinson, and D. J. Hunter. 2001. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286: 3083-3088.
4. Babcock, G. J., L. L. Decker, M. Volk, and D. A. Thorley-Lawson. 1998. EBV persistence in memory B cells in vivo. Immunity 9:395-404.
5. Babcock, G. J., D. Hochberg, and A. D. Thorley-Lawson. 2000. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497-506.
6. Balandraud, N., J. B. Meynard, I. Auger, H. Sovran, B. Mugnier, D. Reviron, J. Roudler, and C. Roudier. 2003. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 48:1223-1228.
7. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480.
8. + T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J. Clin. Investig. 107:121-130.
9. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791-802.
10. Bray, P. F., L. C. Bloomer, V. C. Salmon, M. H. Bagley, and P. D. Larsen. 1983. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch. Neurol. 40:406-408.
11. Bray, P. F., J. Luka, K. W. Culp, and J. P. Schlight. 1992. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 42:1798-1804.
12. Caldwell, R. G., J. B. Wilson, S. J. Anderson, and R. Longnecker. 1998. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405-411.
13. + T cell memory in vivo. Eur. J. Immunol. 28:4382-4390.
14. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187:1395- 1402.
15. + T cells. J. Exp. Med. 184:863-871.
16. Cepok, S., B. Rosche, V. Grummel, F. Vogel, D. Zhou, J. Sayn, N. Sommer, H. P. Hartung, and B. Hemmer. 2005. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128:1667-1676.
17. Cepok, S., D. Zhou, R. Srivastava, S. Nessler, S. Stei, K. Bussow, N. Sommer, and B. Hemmer. 2005. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Investig. 115:1352-1360.
18. Cohen, J. I. 2000. Epstein-Barr virus infection. N. Engl. J. Med. 343:481-492.
19. Colombo, M., M. Dono, P. Gazzola, N. Chiorazzi, G. Mancardi, and M. Ferrarini. 2003. Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients. Eur. J. Immunol. 33:3433-3438.
20. Colombo, M., M. Dono, P. Gazzola, S. Roncella, A. Valetto, N. Chiorazzi, G. L. Mancardi, and M. Ferrarini. 2000. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 164:2782-2789.
21. DeLorenze, G. N., K. L. Munger, E. T. Lennette, N. Orentreich, J. H. Vogelman, and A. Ascherio. 2006. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63:839-844.
22. Evans, A. S. 1971. The spectrum of infections with Epstein-Barr virus: a hypothesis. J. Infect. Dis. 124:330-337.
23. Evans, A. S., N. F. Rothfield, and J. C. Niederman. 1971. Raised antibody titres to E.B. virus in systemic lupus erythematosus. Lancet i:167-168.
24. Fingeroth, J. D., J. J. Weis, T. F. Tedder, J. L. Strominger, P. A. Biro, and D. T. Fearon. 1984. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA 81:4510-4514.
25. Flamand, L., and J. Menezes. 1996. Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6. J. Virol. 70:1784-1791.
26. Frohman, E. M., M. K. Racke, and C. S. Raine. 2006. Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 354:942-955.
27. + T cells in the control of mouse Burkitt lymphoma in vivo. J. Clin. Investig. 114:542-550.
28. Gronen, F., K. Ruprecht, B. Weissbrich, E. Klinker, A. Kroner, H. H. Hofstetter, and P. Rieckmann. 2006. Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J. Neuroimmunol. 180:185-192.
29. Gross, A. J., D. Hochberg, W. M. Rand, and D. A. Thorley-Lawson. 2005. EBV and systemic lupus erythematosus: a new perspective. J. Immunol. 174:6599-6607.
30. Hafler, D. A. 2004. Multiple sclerosis. J. Clin. Investig. 113:788-794.
31. Henle, W., G. Henle, J. Andersson, I. Ernberg, G. Klein, C. A. Horwitz, G. Marklund, L. Rymo, C. Wellinder, and S. E. Straus. 1987. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc. Natl. Acad. Sci. USA 84:570-574.
32. Hjalgrim, H., J. Askling, K. Rostgaard, S. Hamilton-Dutoit, M. Frisch, J. S. Zhang, M. Madsen, N. Rosdahl, H. B. Konradsen, H. H. Storm, and M. Melbye. 2003. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N. Engl. J. Med. 349:1324-1332.
33. Hochberg, D., J. M. Middeldorp, M. Catalina, J. L. Sullivan, K. Luzuriaga, and D. A. Thorley-Lawson. 2004. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc. Natl. Acad. Sci. USA 101:239-244.
34. Hoffman, G. J., S. G. Lazarowitz, and S. D. Hayward. 1980. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. Natl. Acad. Sci. USA 77:2979-2983.
35. Hsiao, F. C., M. Lin, A. Tai, G. Chen, and B. T. Huber. 2006. Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J. Immunol. 177:2056-2060.
36. Humme, S., G. Reisbach, R. Feederle, H. J. Delecluse, K. Bousset, W. Hammerschmidt, and A. Schepers. 2003. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. USA 100:10989-10994.
37. Kamradt, T., and N. A. Mitchison. 2001. Tolerance and autoimmunity. N. Engl. J. Med. 344:655-664.
38. Kang, I., T. Quan, H. Nolasco, S. H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft. 2004. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J. Immunol. 172:1287-1294.
39. Kelly, G. L., A. E. Milner, G. S. Baldwin, A. I. Bell, and A. B. Rickinson. 2006. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 103:14935-14940.
40. Khan, G., E. M. Miyashita, B. Yang, G. J. Babcock, and D. A. Thorley-Lawson. 1996. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 5:173-179.
41. Kurtzke, J. F. 2005. Epidemiology and etiology of multiple sclerosis. Phys. Med. Rehabil. Clin. N. Am. 16:327-349.
42. Laichalk, L. L., and D. A. Thorley-Lawson. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79:1296-1307.
43. Lang, H. L., H. Jacobsen, S. Ikemizu, C. Andersson, K. Harlos, L. Madsen, P. Hjorth, L. Sondergaard, A. Svejgaard, K. Wucherpfennig, D. I. Stuart, J. I. Bell, E. Y. Jones, and L. Fugger. 2002. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3:940-943.
44. Lee, S. P., J. M. Brooks, H. Al-Jarrah, W. A. Thomas, T. A. Haigh, G. S. Taylor, S. Humme, A. Schepers, W. Hammerschmidt, J. L. Yates, A. B. Rickinson, and N. W. Blake. 2004. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199:1409-1420.
45. + T-helper 1 responses. J. Virol. 75:8649-8659.
46. Levin, L. I., K. L. Munger, M. V. Rubertone, C. A. Peck, E. T. Lennette, D. Spiegelman, and A. Ascherio. 2005. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293:2496-2500.
47. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688.
48. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M. G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 94:12616-12621.
49. Li, Q., M. K. Spriggs, S. Kovats, S. M. Turk, M. R. Comeau, B. Nepom, and L. M. Hutt-Fletcher. 1997. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J. Virol. 71:4657-4662.
50. Lindberg, C., O. Andersen, A. Vahlne, M. Dalton, and B. Runmarker. 1991. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 10:62-65.
51. + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J. Virol. 79:4896-4907.
52. Lünemann, J. D., N. Edwards, P. A. Muraro, S. Hayashi, J. I. Cohen, C. Münz, and R. Martin. 2006. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129:1493-1506.
53. + T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability. J. Exp. Med. 191:2159-2170.
54. McClain, M. T., B. D. Poole, B. F. Bruner, K. M. Kaufman, J. B. Harley, and J. A. James. 2006. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum. 54: 360-368.
55. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191:1649-1660.
56. Nielsen, T. R., K. Rostgaard, N. M. Nielsen, N. Koch-Henriksen, S. Haahr, P. S. Sorensen, and H. Hjalgrim. 2007. Multiple sclerosis after infectious mononucleosis. Arch. Neurol. 64:72-75.
57. +-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 77:12088-12104.
58. Operskalski, E. A., B. R. Visscher, R. M. Malmgren, and R. Detels. 1989. A case-control study of multiple sclerosis. Neurology 39:825-829.
59. Ozawa, K., G. Suchanek, H. Breitschopf, W. Bruck, H. Budka, K. Jellinger, and H. Lassmann. 1994. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117:1311-1322.
60. + Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169:1593-1603.
61. Paludan, C., D. Schmid, M. Landthaler, M. Vockerodt, D. Kube, T. Tuschl, and C. Münz. 2005. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307:593-596.
62. Pohl, D., B. Krone, K. Rostasy, E. Kahler, E. Brunner, M. Lehnert, H. J. Wagner, J. Gartner, and F. Hanefeld. 2006. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67:2063-2065.
63. + T cells during primary cytomegalovirus infection. J. Clin. Investig. 105:541-548.
64. Rickinson, A. B., and E. Kieff. 2007. Epstein-Barr virus, p. 2655-2700. In D. M. Knipe and P. M. Howley (ed.), Fields Virology, 5th ed. Wolters Kluwer/Lippincott, Williams & Wilkins, Philadelphia, PA.
65. + T-helper and a T-killer cell. Nature 393:474-478.
66. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483.
67. Sibley, W. A., C. R. Bamford, and K. Clark. 1985. Clinical viral infections and multiple sclerosis. Lancet i:1313-1315.
68. Soldan, S. S., R. Berti, N. Salem, P. Secchiero, L. Flamand, P. A. Calabresi, M. B. Brennan, H. W. Maloni, H. F. McFarland, H. C. Lin, M. Patnaik, and S. Jacobson. 1997. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat. Med. 3:1394-1397.
69. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683-747.
70. Storch, M. K., S. Piddlesden, M. Haltia, M. Iivanainen, P. Morgan, and H. Lassmann. 1998. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43:465-471.
71. Sundstrom, P., P. Juto, G. Wadell, G. Hallmans, A. Svenningsson, L. Nystrom, J. Dillner, and L. Forsgren. 2004. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62: 2277-2282.
72. Sutkowski, N., B. Conrad, D. A. Thorley-Lawson, and B. T. Huber. 2001. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 15:579-589.
73. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827-1835.
74. Thacker, E. L., F. Mirzaei, and A. Ascherio. 2006. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59:499-503.
75. Thorley-Lawson, D. A. 2001. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:75-82.
76. Thorley-Lawson, D. A., and K. Geilinger. 1980. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc. Natl. Acad. Sci. USA 77:5307-5311.
77. Thorley-Lawson, D. A., and C. A. Poodry. 1982. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J. Virol. 43:730-736.
78. Tosato, G., A. D. Steinberg, and R. M. Blaese. 1981. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N. Engl. J. Med. 305: 1238-1243.
79. Tosato, G., A. D. Steinberg, R. Yarchoan, C. A. Heilman, S. E. Pike, V. De Seau, and R. M. Blaese. 1984. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J. Clin. Investig. 73:1789-1795.
80. Tsokos, G. C., I. T. Magrath, and J. E. Balow. 1983. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J. Immunol. 131:1797-1801.
81. Villoslada, P., C. Juste, M. Tintore, V. Llorenc, G. Codina, P. Pozo-Rosich, and X. Montalban. 2003. The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 60:1944-1948.
82. + T cells. Cancer Res. 62:7195-7199.
83. Wandinger, K., W. Jabs, A. Siekhaus, S. Bubel, P. Trillenberg, H. Wagner, K. Wessel, H. Kirchner, and H. Hennig. 2000. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 55: 178-184.
84. Wardemann, H., S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, and M. C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. Science 301:1374-1377.
85. Wucherpfennig, K. W., and J. L. Strominger. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705.
86. Yurasov, S., H. Wardemann, J. Hammersen, M. Tsuiji, E. Meffre, V. Pascual, and M. C. Nussenzweig. 2005. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201:703-711.
87. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.